How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference.

Peyrot M, Rubin RR

Diabetes care26 May 2009Cited by 46 (Europe PMC)

PMID19470837PMCIDPMC2713611DOI10.2337/dc08-2256PepBankPUB-19470837

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide was associated with greater treatment satisfaction than placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide was linked to greater treatment satisfaction than placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseTreatment satisfaction
Study
n = 266
Comparator
Placebo
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
RESULTS Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower me…
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
Report a problemFND-1947083701
02HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide was associated with greater treatment preference than placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide was linked to greater treatment preference than placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseTreatment preference
Study
n = 266
Comparator
Placebo
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
RESULTS Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower me…
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
Report a problemFND-1947083702
03HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide was associated with greater perceived benefits, except hypoglycemia prevention, versus placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide was linked to greater perceived benefits than placebo, except prevention of low blood sugar.
Peptide
Pramlintide (Symlin)
Outcome
IncreasePerceived benefits
Study
n = 266
Comparator
Placebo
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
RESULTS Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower me…
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
Report a problemFND-1947083703
04HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide was associated with weight loss versus placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide was linked to lower weight than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseWeight
Study
n = 266
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
RESULTS Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower me…
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
Report a problemFND-1947083704
05HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide was associated with lower postprandial glucose versus placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide was linked to lower glucose after meals than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose
Study
n = 266
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
RESULTS Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower me…
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
Report a problemFND-1947083705
06HumanRandomized controlled trialSafety outcome
In patients with type 1 diabetes, pramlintide was associated with lower medication tolerance versus placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide was linked to lower medication tolerance than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMedication tolerance
Study
n = 266
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
RESULTS Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower me…
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
Report a problemFND-1947083706
07HumanRandomized controlled trialSafety outcome
In patients with type 1 diabetes, pramlintide was associated with more hypoglycemia versus placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide was linked to more low blood sugar than placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseHypoglycemia
Study
n = 266
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
RESULTS Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower me…
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
Report a problemFND-1947083707

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

08HumanNot a test of Pramlintide (Symlin) aloneObservational studyMechanism
In patients with type 1 diabetes, clinical outcomes explained almost half of the medication effect on satisfaction and preference.
In plain wordsIn patients with type 1 diabetes, clinical outcomes explained almost half of the medication effect on satisfaction and preference.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableClinical outcome mediation
Study
n = 266
Outcome group
Patient-reported outcomes · Metabolic and weight
Source sentences
Summary
Clinical outcomes (especially PPG) accounted for almost half of the effect of the study medication on treatment satisfaction and preference.
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1947083708
09HumanNot a test of Pramlintide (Symlin) aloneObservational studyMechanism
In patients with type 1 diabetes, perceived benefits and side effects mediated most associations between clinical outcomes and satisfaction or preference.
In plain wordsIn patients with type 1 diabetes, perceived effects explained most links between clinical outcomes and treatment satisfaction or preference.
Peptide
Pramlintide (Symlin)
Outcome
Not applicablePerceived consequence mediation
Study
n = 266
Outcome group
Patient-reported outcomes · Metabolic and weight
Source sentences
Summary
Treatment satisfaction and preference were strongly related to the perceived benefits/side effects of the study medication, and these perceptions (especially glucose control) mediated most of the association of clinical outcomes with satisfaction and preference.
1 context sentence(design, population, supporting numbers)
Summary · context
RESEARCH DESIGN AND METHODS The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1947083709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.